Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment
Abrahamsen B., Eiken P., Prieto-Alhambra D., Eastell R.
Osteonecrosis of the jaw (ONJ) is regarded as a rare event in users of oral bisphosphonates whereas it is a common adverse event in an oncology setting where dose intensity is higher and the route is intravenous. Despite this, there is no clear indication that the risk of ONJ increases with increasing treatment time for oral bisphosphonates.